Literature DB >> 9754660

Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer.

M Wagner1, J Kleeff, M E Lopez, I Bockman, J Massaqué, M Korc.   

Abstract

Transforming growth factor-beta (TGF-beta) signaling is initiated following heterodimerization of the type II TGF-beta receptor (TbetaRII) with the type I TGF-beta receptor (TbetaRI). Both receptors are required for TGF-beta responsiveness. In the present study, we characterized the actions of TGF-beta1 in T3M4 human pancreatic cancer cells, which express low levels of TbetaRI and high levels of TbetaRII. Cells were transiently transfected with p3TP-Lux, a TGF-beta-responsive luciferase reporter gene construct. TGF-beta1 was without effect in parental T3M4 cells, but caused a time- and dose-dependent increase in luciferase activity in T3M4 cells co-transfected with a TbetaRI cDNA expression vector. Co-transfection of TbetaRI with a truncated Smad4 cDNA that is known to block TGF-beta-dependent signaling, abrogated the TbetaRI-induced increase in luciferase activity. Sequencing of the TbetaRI and the Smad4 genes in T3M4 cells did not reveal any mutations. These findings indicate that one mechanism for TGF-beta resistance in pancreatic cancer is due to a quantitative decrease in TbetaRI expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754660     DOI: 10.1002/(sici)1097-0215(19981005)78:2<255::aid-ijc21>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.

Authors:  Michiya Yasutome; Jason Gunn; Murray Korc
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway.

Authors:  Katarzyna A Cieslik; Joann Trial; Mark L Entman
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

3.  Transforming growth factor beta-activated kinase 1 is a key mediator of ovine follicle-stimulating hormone beta-subunit expression.

Authors:  Nedal Safwat; Jun Ninomiya-Tsuji; A Jesse Gore; William L Miller
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

4.  Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.

Authors:  H Friess; L Wang; Z Zhu; R Gerber; M Schröder; A Fukuda; A Zimmermann; M Korc; M W Büchler
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

5.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

6.  A control engineering approach to understanding the TGF-β paradox in cancer.

Authors:  Seung-Wook Chung; Carlton R Cooper; Mary C Farach-Carson; Babatunde A Ogunnaike
Journal:  J R Soc Interface       Date:  2011-12-21       Impact factor: 4.118

7.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 8.  SMAD4 and its role in pancreatic cancer.

Authors:  Xiang Xia; Weidong Wu; Chen Huang; Gang Cen; Tao Jiang; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Tumour Biol       Date:  2014-12-03

9.  RUNX3 expression in primary and metastatic pancreatic cancer.

Authors:  J Li; J Kleeff; A Guweidhi; I Esposito; P O Berberat; T Giese; M W Büchler; H Friess
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

10.  AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.

Authors:  A M Norris; A Gore; A Balboni; A Young; D S Longnecker; M Korc
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.